FDA Awards Fast Track Status to TRE-515 for Lung Cancer Treatment
The FDA granted Fast Track designation to TRE-515 combined with KRAS G12C inhibitors for non-small cell lung cancer, marking the drug's second such designation.
The U.S. Food and Drug Administration has granted Fast Track designation to TRE-515 in combination with KRAS G12C inhibitors for the treatment of non-small cell lung cancer, the developer announced Wednesday. The designation marks the second Fast Track status awarded to TRE-515, signaling growing regulatory recognition of the therapy's potential across multiple cancer indications.
Fast Track designation is a program designed by the FDA to accelerate the development and review of drugs that treat serious conditions and fill an unmet medical need. The status allows for more frequent interactions with the agency and eligibility for rolling review, potentially shortening the path from clinical development to patient access.
Read more IBM Adds Private Equity Executive Frank Baker to Board →
Non-small cell lung cancer represents the most common form of lung cancer, and KRAS G12C mutations are among the most prevalent oncogenic drivers identified in the disease. Combination approaches targeting this mutation have become an active area of oncology research as single-agent therapies have encountered resistance challenges.
The second Fast Track designation broadens the oncology opportunity for TRE-515 and is expected to support expedited development efforts spanning several cancer types. Regulatory milestones of this nature are generally viewed as meaningful validation points for emerging oncology compounds navigating early-to-mid stage clinical pipelines.
Continue reading at GlobeNewswire - Industry News on Financial Services.
